Medicine Specific PMCs

To review listed U.S. post marketing commitments for specific Pfizer medicines, select from the search options below.

Search U.S. Post Marketing Commitments

Choose Brand Name:*	All Aromasin Azulfidine Camptosar Cardura Celebrex Cerebyx Chantix Cleocin Depo-Provera Diflucan Eraxis Exubera Fragmin Geodon Inspra Lyrica Neurontin Nicotrol Norvasc Rescriptor Revatio Selzentry Somavert Sutent Vfend Viracept Zinecard Zithromax Zmax Zoloft Zyvox
	OR
Choose Generic Name:*	All Amlodipine Besilate Anidulafungin Azithromycin Celecoxib Clindamycin Phosphate Dalteparin Sodium Delavirdine Mesilate Dexrazoxane Doxazosin Mesilate Eplerenone Exemestane Fluconazole Fosphenytoin Gabapentin Insulin Irinotecan HCl Linezolid Maraviroc Medroxyprogesterone Acetate Nelfinavir Mesilate Nicotine Pegvisomant Pregabalin Sertraline HCl Sildenafil Citrate Sulfasalazine Sunitinib Malate Varenicline Tartrate Voriconazole Ziprasidone HCl
Choose Application Number:	All 19-950 20-235 20-779 20-998 21-131 21-132 21-216 21-267 21-630 21-724 21-938 19-787 19-839 19-949 20-212 20-235 20-246 20-287 20-371 20-385 20-450 20-571 20-705 20-753 20-778 20-825 20-882 20-919 20-998 21-106 21-130 21-156 21-243 21-266 21-437 21-446 21-630 21-632 21-724 21-868 21-928 21-968 22-128 38-505 50-710 50-730 50-767 50-797
Choose Commitment Type:	All Clinical Trial Other Pediatric Pre-Clinical Safety Special Populations
Choose Status:	All Delayed Fulfilled Ongoing Pending Released Submitted Terminated
Choose Approval Date:	From To
Choose Due Date:	From To

About the Information Posted on This Web Site:

This Web site contains information about Pfizer’s U.S. pharmaceutical post marketing commitments. The post marketing commitments listed here include pre-clinical, clinical and epidemiological studies or testing agreed to by Pfizer (including its subsidiaries) and the FDA, and are used to gather additional information about the safety, efficacy, or use of approved Pfizer medicines. This Web site provides the current status of Pfizer post marketing commitments listed on the FDA Web site and includes post marketing commitments established for Pfizer medicines in the U.S. since August 1, 2000. New post marketing commitments will be listed on this Web site as they are established. Released or completed post marketing commitments will be removed from the site.

This Web site does not contain technical chemistry, manufacturing and control (CMC) commitments, or commitments for medicines where Pfizer is not the FDA license holder. Information about Pfizer’s post marketing commitments to the U.S. FDA is believed to be correct at the time that the information is posted, and is subject to change as progress is made in fulfilling the commitments.

This Web site is updated monthly. The status of post marketing commitments shown on the FDA Web site may differ from information displayed on this site, due to differences in the timing of updates made to the FDA Web site. The number of commitments on the two sites may also differ, due to the frequency of such updates and/or due to multiple reporting of single commitments on the FDA Web site.